Published in Adv Exp Med Biol on January 01, 2010
Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 2.10
A novel role of complement in retinal degeneration. Invest Ophthalmol Vis Sci (2012) 0.89
Synthesis and propagation of complement C3 by microglia/monocytes in the aging retina. PLoS One (2014) 0.80
Complement factor H, vitronectin, and opticin are tyrosine-sulfated proteins of the retinal pigment epithelium. PLoS One (2014) 0.76
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01
A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J (2004) 5.33
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology (2005) 3.20
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J (2002) 2.90
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology (2011) 2.65
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 2.57
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol (2006) 2.52
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 2.52
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2005) 2.43
Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med (2003) 2.39
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci (2003) 2.09
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol (2005) 1.97
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest (2002) 1.95
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J (2002) 1.63
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol (2002) 1.57
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci (2004) 1.45
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol (2004) 1.39
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci (2007) 1.38
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.34
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci (2007) 1.32
The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci (2003) 1.28
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci (2006) 1.22
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci (2003) 1.22
Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes (2003) 1.21
VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci (2003) 1.17
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology (2007) 1.12
Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci (2002) 1.11
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis (2006) 1.10
Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci (2003) 1.07
Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea (2003) 1.05
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol (2009) 1.04
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol (2007) 1.03
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci (2003) 1.03
Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am (2006) 1.02
Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res (2002) 0.97
Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol (2003) 0.96
Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin North Am (2002) 0.95
The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest Ophthalmol Vis Sci (2002) 0.93
Targeting the Effect of VEGF in Diabetic Macular Edema. N Engl J Med (2015) 0.93
Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol (2002) 0.91
Mechanisms of age-related macular degeneration. Ophthalmol Clin North Am (2002) 0.90
Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health (2007) 0.90
Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci (2008) 0.90
Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol (2009) 0.86
Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization. Mol Vis (2006) 0.81
Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci (2009) 0.80
Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors. Dev Ophthalmol (2015) 0.77
Judah Folkman. Semin Ophthalmol (2009) 0.75
Ocular delivery of angiostatic agents. Int Ophthalmol Clin (2004) 0.75